Six News Items in Psoriatic Arthritis

Issue: August 2016

Healio Rheumatology spotlights five news items that focus on recently published research about psoriatic arthritis.

Apremilast showed clinically meaningful improvements for PsA treatment

Patients who took twice daily apremilast for treatment of psoriatic arthritis (PsA) showed clinical improvement at 16 weeks and had sustained improvement with continued treatments through 52 weeks compared with a placebo group, according to research. Read more.

Perception of psoriatic arthritis, psoriasis severity impacted patient-reported outcomes

Patient perception of psoriatic arthritis and psoriasis severity negatively influenced patient-reported outcomes, including the frequency and severity of itching, dermatology quality of life and work productivity, and activity impairment measures, according to results presented at the EULAR Annual Congress. Read more.

Positive results seen with bimekizumab in patients with PsA

According to data presented at the EULAR Annual Congress, bimekizumab showed rapid onset, was effective for disease activity in the skin and joints, and was well tolerated by patients with psoriatic arthritis (PsA). Read More.

Study links coexisting fibromyalgia to poorer test scores in patients with PsA

Results from this study indicated patients who had psoriatic arthritis (PsA) and coexisting fibromyalgia had poor scores on all tested measures. Read more.

Phase 3 study shows positive results with tofacitinib citrate for psoriatic arthritis

Pfizer Inc. announced positive results from its phase 3 study that evaluated tofacitinib citrate in patients with active psoriatic arthritis, according to a recent press release. Read more.

Study shows association between baseline patient characteristics, development of erosions in PsA cohort

Recently published results showed an association between baseline patient characteristics and the development of erosions among patients with psoriatic arthritis (PsA). Read more.